Cargando…
Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223154/ https://www.ncbi.nlm.nih.gov/pubmed/27935578 http://dx.doi.org/10.1038/bcj.2016.119 |
| _version_ | 1782493121305640960 |
|---|---|
| author | Tong, W H |
| author_facet | Tong, W H |
| author_sort | Tong, W H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5223154 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-52231542017-01-13 Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' Tong, W H Blood Cancer J Letter to the Editor Nature Publishing Group 2016-12 2016-12-09 /pmc/articles/PMC5223154/ /pubmed/27935578 http://dx.doi.org/10.1038/bcj.2016.119 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Tong, W H Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title | Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title_full | Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title_fullStr | Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title_full_unstemmed | Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title_short | Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| title_sort | comment on 'blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223154/ https://www.ncbi.nlm.nih.gov/pubmed/27935578 http://dx.doi.org/10.1038/bcj.2016.119 |
| work_keys_str_mv | AT tongwh commentonblinatumomabvshistoricalstandardtherapyofadultrelapsedrefractoryacutelymphoblasticleukemia |